Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial

This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.

Authors

Institutions

Publication Details

Journal
Clinical Diabetes
Published
2024-09-09
DOI
https://doi.org/10.2337/cd24-0003
Citations
4
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
1.43

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial

Hana Kahleová, Martin Haluzı́k, Barry A. Borlaug, Tomáš Čajka et al.
4 citations
Clinical Diabetes
Diabetes Treatment and Management
1.43
article

Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial

Hana Kahleová, Martin Haluzı́k, Barry A. Borlaug, Tomáš Čajka, Martin Hill, Ondřej Kuda, Jiří Veleba, KATERINA VELEBOVA, Lenka Thieme, Vojtěch Melenovský, Eva Hošková, Markéta Segeťová, Ján Kopecký, Jan Beneš, Terezie Pelikánová
article en
4 citations

Abstract

This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.

Clinical DiabetesVol. 43(1)
Physicians Committee for Responsible Medicine (US), Czech Academy of Sciences (CZ), Mayo Clinic in Arizona (US), Institute of Clinical and Experimental Medicine (CZ), Institute of Endocrinology (CZ), Czech Academy of Sciences, Institute of Physiology (CZ)
European Commission
Good health and well-being
Openalex Percentile: Top 16%
Diabetes Treatment and Management
1.43
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.